Comparative Pharmacology
Head-to-head clinical analysis: NAPROSYN versus TENATHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROSYN versus TENATHAN.
NAPROSYN vs TENATHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
TENATHAN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, leading to increased serotonin levels in the synaptic cleft.
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
1 tablet (40 mg) orally once daily, increased to 80 mg once daily if needed after 4 weeks.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Terminal elimination half-life is 4-6 hours; in severe renal impairment (CrCl <30 mL/min) may extend to 8-12 hours, requiring dose adjustment.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Primarily renal excretion as unchanged drug (60-70%) and metabolites (20-30%); biliary/fecal elimination accounts for <10%.
Category C
Category C
NSAID
NSAID